NEW YORK/HELSINKI (Reuters)—Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the anti-malarial drug hydroxychloroquine (HCQ) that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker’s chief executives. Amneal has committed to producing about 20 million…
Search results for: hospital
A Collaborative Website as a Communication Model During the COVID-19 Pandemic
Under the onslaught of developing information on COVID-19, one health system found a way to streamline communication using a secure tool it already had access to.
JIA & the Temporomandibular Joint: Diagnostic Challenges & Treatment Options
Juvenile idiopathic arthritis (JIA) can affect all joints, including the temporomandibular joints (TMJs). For a long time, the TMJ was a “forgotten” joint in pediatric rheumatology, although Sir Frederick Still did comment on a small mandible in his first case series on juvenile arthritis in 1897. In recent years, more attention has been given to…
Tocilizumab Begins Clinical Trial for COVID-19
The FDA has authorized a phase 3 clinical trial examining the safety and efficacy of tocilizumab plus standard care in patients hospitalized with COVID-19…
Resolving Inflammation: Research on Signals & Mediators Continues to Advance
Researchers discuss new insights into inflammation signals and mediators…
Diagnosing Anti-MOG Autoimmune Encephalomyelitis
A case study of a 7-year-old girl who is eventually diagnosed with anti-MOG autoimmune encephalomyelitis highlights the necessity of a multi-disciplinary approach to inflammatory brain disease…
Should Biologic Therapy in Dermatology Be Interrupted During the Pandemic?
NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the…
Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug
PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an…
Providing the Best Care: Rheumatologists & Professionals Adapt to COVID-19
The new landscape for rheumatologists includes telemedicine, kids out of school and infection-prevention protocols. During the current pandemic, the practice of medicine, research and daily lives are changing to keep providers and patients safe…
Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada…
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 324
- Next Page »